Select a State

Global health R&D delivers for Utah

US government investment in global health R&D has delivered

$22.3 million
to Utah research institutions
350+ new jobs
for Utah

Neglected diseases in Utah

Chikungunya cases
6
Dengue cases
8
HIV diagnoses
1,044
Malaria cases
48
Tuberculosis cases
276
West Nile cases
68
Zika cases
26

Utah's top USG-funded global health R&D institutions

University of Utah
$19.0 million
Utah State University
$2.6 million
Brigham Young University
$720 thousand

Utah industry in global health R&D

Biofire
Location(s):
Salt Lake City
Navigen
Location(s):
Salt Lake City

Utah's top areas of global health R&D by USG funding

31.6%
HIV/AIDS
10.1%
Malaria
5.7%
Diarrheal diseases
2.4%
Ebola/viral hemorrhagic fevers
9.1%
Salmonella infections
12.4%
Neglected tropical diseases
Dengue
Kinetoplastids
28.8%
Other
Non-allocable
Tuberculosis

Global health R&D at work in Utah

Researchers at Utah State University supported preclinical testing that showed that a promising new antiviral drug now in development to treat Ebola and Marburg also holds potential to treat Zika. The study was supported by the Animal Models of Infectious Disease Program at the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health. The program is part of NIAID's infrastructure for responding to emerging infectious diseases. Linked to devastating birth defects, the Zika virus affected millions of people across 80 countries, including over 49,000 cases in the United States and its territories. The Utah State study yielded important insights that could lead to a treatment for the disease.

Footnotes